By: Option Care
October 30, 2017

100 多名 ALS 患者已经开始在舒适的家中接受使用 RadicavaTM 的 Option Care 护理

全国性家庭输液服务提供者 Option Care 与 ALS 协会合作伊利诺伊州班诺克本,2017 年 10 月 30 日 — Option Care Enterprises, Inc., the nation’s largest independent provider of home and alternate treatment site infusion therapy services, has partnered with The ALS Association to offer education, support and enhance the quality of life for individuals affected by amyotrophic lateral sclerosis (ALS).

随着 RADICAVATM (edaravone) 获得批准,成为食品药品监督管理局 (FDA) 20 多年来批准的首个 ALS 治疗方案,现在家庭输液服务的需求不断增加。Option Care 为成为 RADICAVATM (edaravone) 全美签约的家庭输液服务提供者而自豪,通过向 ALS 患者提供在舒适的家中接受治疗的能力来支持 ALS 社区。现在已有超过 100 家护理中心成功开始使用 RadicavaTM (edaravone)。此外,Option Care 还为许多 ALS 患者提供了业界领先的营养支持项目和肠内治疗。

“Option Care applauds The ALS Association’s mission and recognizes their efforts in giving help and hope to those facing the disease,” said John Rademacher, CEO, Option Care. “We look forward to this new partnership with The ALS Association and the ability to be part of providing education, support and services to those living with the disease.”

“We’re deeply grateful for Option Care’s willingness to support our mission of helping people with ALS and their families,” said Calaneet Balas, Executive Vice President of Strategy for The ALS Association. “We’re proud to partner with Option Care as its services are more critical now than ever.”

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is one of the nation’s largest and most trusted providers of home and alternate treatment site infusion services. An industry leader, the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.

About The ALS Association
The ALS Association is the only national non-profit organization fighting Lou Gehrig’s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at  www.alsa.org.

重要的安全信息

在您接受 RADICAVA 治疗之前,请将您的所有健康状况告知您的医疗保健服务提供者,包括以下状况:

  • have asthma.
  • 对其他药物过敏。
  • 怀孕或计划怀孕。RADICAVA 对胎儿是否有害尚不清楚。
  • 母乳喂养或计划母乳喂养。RADICAVA 是否会进入乳汁尚不清楚。您和您的医疗保健提供者应决定您要接受 RADICAVA 治疗还是进行母乳喂养。

将您服用的所有药物告知您的医疗保健服务提供者,包括处方药和非处方药、维生素和草药补充剂。

RADICAVA 可能会有哪些副作用?

  • RADICAVA 可能会引起严重的副作用,包括超敏(过敏)反应和亚硫酸盐过敏反应。
  • 接受 RADICAVA 治疗的人士曾出现过超敏反应,可能在您的输液完成后发生。
  • RADICAVA 含有亚硫酸氢钠,这种亚硫酸盐可能导致一种严重且危及生命的过敏反应。亚硫酸氢钠也可能导致某些人士出现不太严重的哮喘发作。哮喘病患者比非哮喘病患者更经常出现亚硫酸盐过敏。
  • 如果您有以下任何症状,应立即告知您的医疗保健服务提供者或前往最近的急诊室就医:荨麻疹;嘴唇、舌头或面部肿胀;昏厥;呼吸问题;喘息;吞咽困难;头晕;瘙痒;或(哮喘患者)哮喘发作。
  • Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects.

RADICAVA 最常见的副作用包括瘀伤(挫伤)、行走困难(步履不稳)和头痛。

这些并非 RADICAVA 所有可能产生的副作用。致电您的医疗保健提供者咨询相关副作用。您可以向 Mitsubishi Tanabe Pharma America, Inc. 报告副作用:1-888-292-0058 或 FDA:1-800-FDA-1088 或访问 www.fda.gov/medwatch

要了解更多信息,包括完整的处方信息和患者信息,请访问 www.RADICAVA.com

Share Post